Identification

Name
Mannitol
Accession Number
DB00742  (APRD01083, EXPT02246)
Type
Small Molecule
Groups
Approved, Investigational
Description

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. Mannitol may also be used for the promotion of diuresis before irreversible renal failure becomes established; the promotion of urinary excretion of toxic substances; as an Antiglaucoma agent; and as a renal function diagnostic aid.

Structure
Thumb
Synonyms
  • (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
  • (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
  • D-(-)-Mannitol
  • D-Mannitol
  • e 421
  • e421
  • Fraxinine
  • Manitol
  • Manna Sugar
  • Mannit
  • Mannite
  • Mannitol
  • Mannitolum
External IDs
E-421 / INS NO.421 / INS-421
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis2012-04-13Not applicableEu
BronchitolCapsule40 mgRespiratory (inhalation)Pharmaxis2012-04-13Not applicableEu
MannitolIrrigant5 g/100mLIrrigationB. Braun Medical Inc.1978-02-10Not applicableUs
MannitolInjection, solution15 g/100mLIntravenousHospira, Inc.2005-08-31Not applicableUs
MannitolInjection, solution20 g/100mLIntravenousB. Braun Medical Inc.1993-07-26Not applicableUs
MannitolInjection, solution12.5 g/50mLIntravenousHospira, Inc.2004-11-30Not applicableUs
MannitolInjection, solution10 g/100mLIntravenousHospira, Inc.2006-04-112010-09-01Us
MannitolInjection, solution12.5 g/50mLIntravenousCardinal Health2010-02-01Not applicableUs
MannitolInjection, solution20 g/100mLIntravenousHospira, Inc.2005-09-19Not applicableUs
MannitolInjection, solution5 g/100mLIntravenousHospira, Inc.2005-08-222010-10-01Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MannitolInjection, solution250 mg/1mLIntravenousAmerican Regent1990-09-30Not applicableUs
MannitolInjection, solution250 mg/1mLIntravenousFresenius Kabi2000-03-19Not applicableUs
MannitolInjection, solution250 mg/1mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GD11 Rx SCM C5Liquid0.10 g/2mLTopicalCoson Co., Ltd.2017-07-01Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Additive Solution Sodium Adenine Glucose Mannitol (sagm)Mannitol (5.25 g) + Adenine (0.169 g) + Dextrose, unspecified form (9 g) + Sodium Chloride (8.77 g)SolutionUnknownMaco Pharma2016-08-22Not applicableCanada
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (750 mg/100mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) + Sodium phosphate, monobasic, monohydrate (140 mg/63mL)KitFenwal, Inc.2010-05-25Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (750 mg/100mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) + Sodium phosphate, monobasic, monohydrate (140 mg/63mL)KitFenwal, Inc.2010-09-28Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (750 mg/100mL) + Adenine (27 mg/100mL) + Citric Acid (188 mg/63mL) + D-glucose monohydrate (1.61 g/63mL) + D-glucose monohydrate (2.2 g/100mL) + Sodium Chloride (900 mg/100mL) + Sodium citrate dihydrate (1.66 g/63mL) + Sodium phosphate, monobasic, monohydrate (140 mg/63mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2007-06-04Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2007-06-11Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2007-03-01Not applicableUs
ADSOL Red Cell Preservation Solution System in Plastic Container (PL 146 Plastic)Mannitol (825 mg/110mL) + Adenine (30 mg/110mL) + Citric Acid (209 mg/70mL) + D-glucose monohydrate (1.78 g/70mL) + D-glucose monohydrate (2.42 g/110mL) + Sodium Chloride (990 mg/110mL) + Sodium citrate dihydrate (1.84 g/70mL) + Sodium phosphate, monobasic, monohydrate (155 mg/70mL)KitFenwal, Inc.2009-05-15Not applicableUs
International/Other Brands
Anol (Astar) / Aridol (Pharmaxis) / Bronchitol (Pharmaxis) / Deltamannit (DeltaSelect) / Demanitol (Medifarma) / Diurecide (Lusa) / Isotol / Manicol / Manit (Pliva) / Manitol Mein (Fresenius) / Maniton / Mannigen / Mannisol (Human Co. Ltd.) / Mannisol A (Teva) / Mannit / Mannit-Lösung (Serag-Wiessner) / Mannite Actipharm (Actipharm) / Osmitrol / Osmofundin (B. Braun) / Osmohale (Pharmaxis) / Osmosol (Beximco) / Osmosteril (Fresenius) / Resectisol (B. Braun)
Categories
UNII
3OWL53L36A
CAS number
69-65-8
Weight
Average: 182.1718
Monoisotopic: 182.07903818
Chemical Formula
C6H14O6
InChI Key
FBPFZTCFMRRESA-KVTDHHQDSA-N
InChI
InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1
IUPAC Name
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

Pharmacology

Indication

Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.

Associated Conditions
Associated Therapies
Pharmacodynamics

Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.

Mechanism of action

Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).

Absorption

Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.

Volume of distribution
Not Available
Protein binding

None

Metabolism

Mannitol is metabolized only slightly, if at all, to glycogen in the liver.

Route of elimination

It is rapidly excreted in the urine.

Half life

100 minutes

Clearance
Not Available
Toxicity

LD50=1700 mg/kg (rat oral)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Glycolysis and Pyruvate DehydrogenaseMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirMannitol may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbemaciclibThe serum concentration of Mannitol can be increased when it is combined with Abemaciclib.
AcarboseMannitol may decrease the excretion rate of Acarbose which could result in a higher serum level.
AcebutololThe risk or severity of hyperkalemia can be increased when Mannitol is combined with Acebutolol.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Aceclofenac.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Acemetacin.
AcetaminophenThe serum concentration of Mannitol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Mannitol.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Acetylsalicylic acid.
AclidiniumMannitol may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Food Interactions
Not Available

References

Synthesis Reference

Walter M. Kruse, "Process for preparing mannitol from glucose." U.S. Patent US4029878, issued August, 1956.

US4029878
General References
  1. Cruz J, Minoja G, Okuchi K: Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: a randomized trial. Neurosurgery. 2001 Oct;49(4):864-71. [PubMed:11564247]
  2. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery. 2002 Sep;51(3):628-37; discussion 637-8. [PubMed:12188940]
  3. Cruz J, Minoja G, Okuchi K, Facco E: Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial. J Neurosurg. 2004 Mar;100(3):376-83. [PubMed:15035271]
  4. Roberts I, Smith R, Evans S: Doubts over head injury studies. BMJ. 2007 Feb 24;334(7590):392-4. [PubMed:17322250]
  5. Wakai A, Roberts I, Schierhout G: Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001049. [PubMed:16235278]
  6. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187]
External Links
Human Metabolome Database
HMDB0000765
KEGG Drug
D00062
KEGG Compound
C00392
PubChem Compound
6251
PubChem Substance
46506446
ChemSpider
6015
BindingDB
50142798
ChEBI
16899
ChEMBL
CHEMBL689
Therapeutic Targets Database
DAP000874
PharmGKB
PA450320
HET
MTL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Mannitol
ATC Codes
B05CX04 — MannitolB05BC01 — MannitolA06AD16 — MannitolR05CB16 — Mannitol
AHFS Codes
  • 40:36.00 — Irrigating Solutions
  • 36:40.00 — Kidney Function
  • 40:28.12 — Osmotic Diuretics
PDB Entries
1m2w / 1p6k / 1rs6 / 1rs7 / 1zzq / 1zzu / 2vfu / 3n62 / 3n65 / 3n66
show 7 more
FDA label
Download (50 KB)
MSDS
Download (72.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceAllergies / Asthma Bronchial / Lung Diseases, Obstructive / Reactive Airways Disease (RAD)1
1Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
1CompletedTreatmentCystic Fibrosis (CF)2
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentMalaria, Cerebral / Plasmodium Infections1
1CompletedTreatmentPain NOS1
1TerminatedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Long-Term Effects Secondary to Cancer Therapy in Children1
1TerminatedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedNot AvailableBronchiectasis1
1, 2CompletedPreventionAcute Gastroenteritis / Norwalk Virus Infection1
1, 2CompletedTreatmentPostherpetic Neuralgia1
1, 2RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Oligoastrocytoma / Recurrent Adult Brain Neoplasm1
1, 2RecruitingTreatmentCentral Nervous System Lymphoma1
1, 2RecruitingTreatmentDiabetic Peripheral Neuropathy (DPN)1
1, 2SuspendedTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Adult Ependymoblastoma / Adult Medulloblastoma / Adult Pineoblastoma / Adult Supratentorial Embryonal Tumor, Not Otherwise Specified / Adult Supratentorial Primitive Neuroectodermal Tumor / Atypical Teratoid/Rhabdoid Tumor / Central Nervous System Embryonal Tumor / Childhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Embryonal Tumor With Multilayered Rosettes, C19MC-Altered / Childhood Ependymoblastoma / Germ Cell Tumors / Medulloepithelioma / Ototoxicity / Recurrent Adult Brain Neoplasm / Recurrent Childhood Central Nervous System Embryonal Neoplasm / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor1
1, 2Unknown StatusTreatmentSevere Head Trauma1
1, 2WithdrawnNot AvailableEndothelial Dysfunction / Insulin Resistance1
1, 2WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Exacerbation1
2Active Not RecruitingOtherIntra-dialytic Hypotension1
2Active Not RecruitingTreatmentRadiation Necrosis1
2CompletedBasic ScienceHealthy Volunteers2
2CompletedPreventionAcute Renal Failure (ARF) / Renal Dysfunction / The Mortality Rate1
2CompletedPreventionCisplatin Nephrotoxicity1
2CompletedTreatmentCystic Fibrosis (CF)3
2CompletedTreatmentOpioid Dependence1
2RecruitingTreatmentAlcohol Use Disorder (AUD)1
2Unknown StatusTreatmentCystic Fibrosis (CF) / Pneumonia1
2Unknown StatusTreatmentStrokes1
2WithdrawnTreatmentCerebrovascular Accident, Acute / Edema of the cerebrum1
2, 3TerminatedTreatmentIntracranial Pressure Increase / Severe Trauma Brain Injury1
3CompletedDiagnosticAsthma Bronchial1
3CompletedTreatmentBronchiectasis2
3CompletedTreatmentCystic Fibrosis (CF)1
3CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
3CompletedTreatmentRenal Cancers1
3CompletedTreatmentWheezing1
3Not Yet RecruitingTreatmentCiguatoxin1
3RecruitingOtherAsthma Bronchial1
3RecruitingTreatmentHypoxic-Ischaemic Encephalopathy / Infant, Newborn, Diseases1
3RecruitingTreatmentKidney Transplantation, Mannitol1
3TerminatedTreatmentAcute Ischemic Stroke (AIS)1
3TerminatedTreatmentDopamine Beta Hydroxylase Deficiency / Multiple Systems Atrophy / Parkinson's Disease (PD) / Progressive autonomic failure / Symptomatic Neurogenic Orthostatic Hypotension1
3TerminatedTreatmentElevated Intracranial Pressure / Traumatic Brain Injury (TBI)1
3TerminatedTreatmentTraumatic Brain Injury (TBI)1
3Unknown StatusTreatmentFetal Hypoxia / Reperfusion Injury1
3Unknown StatusTreatmentMalaria, Cerebral1
4CompletedNot AvailableBowel preparation therapy1
4CompletedNot AvailableBrain Swelling1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticFood Allergy1
4CompletedDiagnosticUreteral Patency1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentIntracranial Pressure Increase1
4CompletedTreatmentPsoriasis / Sleep Apnea, Obstructive1
4RecruitingTreatmentBrain Swelling / Electrolyte and fluid balance conditions / Metabolic Disturbances1
4TerminatedNot AvailableIntracranial Pressure Increase / Traumatic Brain Injury (TBI)1
4Unknown StatusTreatmentIntracranial Pressure / Osmotherapy1
4Unknown StatusTreatmentRetinopathy, Diabetic1
Not AvailableActive Not RecruitingTreatmentNeoplasms, Kidney1
Not AvailableCompletedNot AvailableProstate Cancer1
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceCystic Fibrosis (CF)1
Not AvailableCompletedBasic SciencePain NOS1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedPreventionIntraocular Pressure Change in Intravitreal Injection1
Not AvailableCompletedTreatmentHand, Foot, and Mouth Disease1
Not AvailableCompletedTreatmentIntracranial Pressure / Neoplasms, Brain1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentAcute fulminant liver failure1
Not AvailableNot Yet RecruitingNot AvailableEdema of the cerebrum / Intracranial Pressure Increase1
Not AvailableRecruitingBasic ScienceAsthma Bronchial1
Not AvailableRecruitingDiagnosticCTE1
Not AvailableRecruitingTreatmentSupratentorial Tumors1
Not AvailableRecruitingTreatmentAcute fulminant liver failure1
Not AvailableWithdrawnTreatmentElevated Intracranial Pressure1
Not AvailableWithdrawnTreatmentTraumatic Brain Injury (TBI)1

Pharmacoeconomics

Manufacturers
  • B braun medical inc
  • Hospira inc
  • Miles laboratories inc
  • Abraxis pharmaceutical products
  • App pharmaceuticals llc
  • Astrazeneca lp
  • International medication system
  • Luitpold pharmaceuticals inc
  • Merck and co inc
  • Watson laboratories inc
  • Baxter healthcare corp
Packagers
  • American Regent
  • APP Pharmaceuticals
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Hospira Inc.
  • Luitpold Pharmaceuticals Inc.
  • Mallinckrodt Inc.
  • Organon Pharmaceuticals
Dosage forms
FormRouteStrength
Kit
CapsuleRespiratory (inhalation)40 mg
LiquidIrrigation
LiquidTopical0.10 g/2mL
KitIntravenous
Injection, solutionIntravenous12.5 g/50mL
Injection, solutionIntravenous250 mg/1mL
IrrigantIrrigation5 g/100mL
LiquidIntravenous100 mg
LiquidIntravenous250 mg
LiquidIntravenous50 mg
SolutionIntravenous250 mg
SolutionIntravenous12.5 g
SolutionIntravenous200 mg
Injection, solutionIntravenous10 g/100mL
Injection, solutionIntravenous15 g/100mL
Injection, solutionIntravenous20 g/100mL
Injection, solutionIntravenous5 g/100mL
LiquidIntravenous10 g
SolutionIntravenous20 g
LiquidIrrigation5 %
SolutionUnknown
SolutionIrrigation
IrrigantUrethral
Prices
Unit descriptionCostUnit
Osmitrol 20% iv solution0.15USD ml
Osmitrol 10% iv solution0.07USD ml
Osmitrol 15% iv solution0.07USD ml
Mannitol powder0.05USD g
Mannitol 15% iv solution0.04USD ml
Mannitol 20% iv solution0.04USD ml
Mannitol 25% vial0.03USD ml
Osmitrol 5% iv solution0.03USD ml
Mannitol 10% iv solution0.02USD ml
Mannitol 5% iv solution0.02USD ml
Resectisol 5% solution0.01USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168 °CPhysProp
boiling point (°C)290-295 °C at 3.50E+00 mm HgPhysProp
water solubility2.16E+005 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-3.10HANSCH,C ET AL. (1995)
Caco2 permeability-6.21ADME Research, USCD
pKa13.5 (at 25 °C)BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility229.0 mg/mLALOGPS
logP-2.7ALOGPS
logP-3.7ChemAxon
logS0.1ALOGPS
pKa (Strongest Acidic)12.59ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area121.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity38.4 m3·mol-1ChemAxon
Polarizability17.04 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6525
Blood Brain Barrier-0.5997
Caco-2 permeable-0.8958
P-glycoprotein substrateNon-substrate0.662
P-glycoprotein inhibitor INon-inhibitor0.9535
P-glycoprotein inhibitor IINon-inhibitor0.9551
Renal organic cation transporterNon-inhibitor0.9252
CYP450 2C9 substrateNon-substrate0.8706
CYP450 2D6 substrateNon-substrate0.878
CYP450 3A4 substrateNon-substrate0.7431
CYP450 1A2 substrateNon-inhibitor0.824
CYP450 2C9 inhibitorNon-inhibitor0.9419
CYP450 2D6 inhibitorNon-inhibitor0.9412
CYP450 2C19 inhibitorNon-inhibitor0.9232
CYP450 3A4 inhibitorNon-inhibitor0.9402
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.958
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7823
BiodegradationReady biodegradable0.8595
Rat acute toxicity1.1260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9709
hERG inhibition (predictor II)Non-inhibitor0.9329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.14 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (6 TMS)GC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MS (6 TMS)GC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0229-9100000000-5655e9df8e0fdcaa72a0
GC-MS Spectrum - EI-BGC-MSsplash10-001i-9200000000-0dad802ab0000303cb33
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0ktb-0931000000-b481d576c5f24dd1b1d5
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-20043a375d72ca08dce9
GC-MS Spectrum - GC-MSGC-MSsplash10-066r-1974000000-38a4beaca17ab8c750b6
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-066s-0942000000-f4df881aeebac32de5c7
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-014j-9600000000-26f4335f7ef7c81ca261
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-066r-9000000000-73db1fbd51fb8c061bec
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-05mo-9000000000-45a4dea1d21286c4b8da
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0089-6900000000-961d76d6550bc342ffa1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0089-6900000000-061f88989a6ac71321e3
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0ik9-1900000000-eb8ea056f3b1dfe2fb1f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-1900000000-6768b4744e1a4e56b18b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kb-1900000000-0765563624accf132d03
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00dr-0900000000-e159f4e76b7847313f35
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0900-0910000000-8d56394cbc78dd3b5ca0
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0079-0900000000-63517bff4abfbf09e1ca
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0w2l-0940000000-dc20c851073dcbc4dba9
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as sugar alcohols. These are hydrogenated forms of carbohydrate in which the carbonyl group (aldehyde or ketone, reducing sugar) has been reduced to a primary or secondary hydroxyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Sugar alcohols
Alternative Parents
Monosaccharides / Secondary alcohols / Polyols / Primary alcohols / Hydrocarbon derivatives
Substituents
Sugar alcohol / Monosaccharide / Secondary alcohol / Polyol / Hydrocarbon derivative / Primary alcohol / Alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
mannitol (CHEBI:16899)

Enzymes

Kind
Protein
Organism
Pseudomonas fluorescens
Pharmacological action
Unknown
Actions
Substrate
General Function
Nucleotide binding
Specific Function
Not Available
Gene Name
mtlD
Uniprot ID
O08355
Uniprot Name
Mannitol dehydrogenase
Molecular Weight
54497.41 Da
References
  1. Wang YM, van Eys J: Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr. 1981;1:437-75. [PubMed:6821187]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2018 07:51